Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
Posted inCardiology Internal Medicine news

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.
Predicting Post-Hepatectomy Liver Failure with the PILOT Architecture: Integrating Liver Regeneration Biomarkers and Time-Phased Machine Learning
Posted inAI General Surgery news

Predicting Post-Hepatectomy Liver Failure with the PILOT Architecture: Integrating Liver Regeneration Biomarkers and Time-Phased Machine Learning

The novel PILOT machine learning architecture integrates time-phased perioperative data and regeneration-associated biomarkers to predict post-hepatectomy liver failure within six hours of surgery, significantly outperforming traditional clinical models and enabling early personalized risk stratification.
Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
Posted inCardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.
Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage
Posted inCardiology Emergency Medicine news

Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage

A secondary analysis of the APACE study demonstrates that Cardiac Myosin-Binding Protein C (cMyC) significantly improves NSTEMI diagnosis, particularly in early presenters. Integrating cMyC with high-sensitivity troponin into a dual-biomarker strategy doubles triage efficacy without compromising safety, offering a robust tool for busy clinical settings.
Lower Posttreatment Amyloid Predicts Slower Clinical Decline and Reduced Tau/Glial Biomarkers After Donanemab: Secondary Analysis of TRAILBLAZER‑ALZ 2
Posted inNeurology news

Lower Posttreatment Amyloid Predicts Slower Clinical Decline and Reduced Tau/Glial Biomarkers After Donanemab: Secondary Analysis of TRAILBLAZER‑ALZ 2

A secondary analysis of TRAILBLAZER‑ALZ 2 found that lower posttreatment amyloid plaque levels after donanemab correlate strongly with less clinical decline and reductions in plasma p‑tau217, p‑tau181, and GFAP over 76 weeks, supporting plaque removal as a likely mechanism of benefit.